NASDAQ:ARCTArcturus Therapeutics Stock Price, Forecast & News

Arcturus Therapeutics' stock was trading at $13.09 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ARCT stock has increased by 197.5% and is now trading at $38.94. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Arcturus Therapeutics.

Arcturus Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 20th 2020. View our earnings forecast for Arcturus Therapeutics.

Arcturus Therapeutics Ltd (NASDAQ:ARCT) issued its earnings results on Thursday, May, 7th. The biotechnology company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.59) by $0.08. The biotechnology company earned $2.65 million during the quarter, compared to analysts' expectations of $7.52 million. Arcturus Therapeutics had a negative return on equity of 409.05% and a negative net margin of 151.34%. View Arcturus Therapeutics' earnings history.

6 equities research analysts have issued 1-year price targets for Arcturus Therapeutics' stock. Their forecasts range from $18.00 to $62.00. On average, they expect Arcturus Therapeutics' share price to reach $29.50 in the next twelve months. This suggests that the stock has a possible downside of 24.2%. View analysts' price targets for Arcturus Therapeutics.

Media coverage about ARCT stock has trended extremely negative recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Arcturus Therapeutics earned a coverage optimism score of -4.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutArcturus Therapeutics.

Arcturus Therapeutics saw a increase in short interest in April. As of April 30th, there was short interest totaling 335,000 shares, an increase of 58.3% from the April 15th total of 211,600 shares. Based on an average trading volume of 218,700 shares, the days-to-cover ratio is currently 1.5 days. Approximately 3.8% of the company's stock are short sold. View Arcturus Therapeutics' Current Options Chain.

Some companies that are related to Arcturus Therapeutics include Arena Pharmaceuticals (ARNA), FibroGen (FGEN), Uniqure (QURE), HUTCHISON CHINA/S (HCM), Axsome Therapeutics (AXSM), Amarin (AMRN), Taro Pharmaceutical Industries (TARO), Alkermes (ALKS), Apellis Pharmaceuticals (APLS), Turning Point Therapeutics (TPTX), Insmed (INSM), Karuna Therapeutics (KRTX), Intercept Pharmaceuticals (ICPT), Ra Pharmaceuticals (RARX) and Prestige Consumer Healthcare (PBH). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Opko Health (OPK), Crispr Therapeutics (CRSP), Pfizer (PFE), Sanofi (SNY), Abbott Laboratories (ABT), Intel (INTC) and Ocular Therapeutix (OCUL).

Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT."

Arcturus Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Dfpg Investments LLC (2.09%), Cormorant Asset Management LP (1.32%), Nikko Asset Management Americas Inc. (1.33%), Sumitomo Mitsui Trust Holdings Inc. (1.33%), Nikko Asset Management Americas Inc. (1.32%) and Morgan Stanley (1.02%). Company insiders that own Arcturus Therapeutics stock include Andy Sassine, Joseph E Payne, Magda Marquet and Peter C Farrell. View institutional ownership trends for Arcturus Therapeutics.

ARCT stock was sold by a variety of institutional investors in the last quarter, including Dfpg Investments LLC, DAFNA Capital Management LLC, Two Sigma Investments LP, JPMorgan Chase & Co., Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., and Creative Planning. View insider buying and selling activity for Arcturus Therapeutics.

ARCT stock was acquired by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Morgan Stanley, Morgan Stanley, Engineers Gate Manager LP, Jane Street Group LLC, Acadian Asset Management LLC, Wells Fargo & Company MN, and Trexquant Investment LP. Company insiders that have bought Arcturus Therapeutics stock in the last two years include Andy Sassine, Joseph E Payne, Magda Marquet, and Peter C Farrell. View insider buying and selling activity for Arcturus Therapeutics.

Shares of ARCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ARCT stock can currently be purchased for approximately $38.94.

Arcturus Therapeutics has a market capitalization of $774.52 million and generates $20.79 million in revenue each year. The biotechnology company earns $-25,990,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis. Arcturus Therapeutics employs 72 workers across the globe.

The official website for Arcturus Therapeutics is www.arcturusrx.com.

Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-900-2660 or via email at [email protected]